Healthgen embraces biotech breakthrough

As the first of its kind in the world, plant-derived recombinant human serum albumin developed by a Chinese biotechnology company is set to be industrialized and commercialized, bringing new hope to patients.

In February, Wuhan Healthgen Biotechnology Corp announced that it had successfully completed phase III clinical trials for plant-derived recombinant human serum albumin for hypoalbuminemia patients. According to the results, its curative efficacy was not inferior to plasma-derived human serum albumin in terms of safety and tolerance.

Human serum albumin is among several indispensable therapeutic biologics for various diseases, an essential emergency medicine for hospitals, and a key excipient for biopharmaceuticals. It is also widely used in vaccine production, supplements for cell culture media and other fields.